Gastrointestinal adverse events associated with use of biologic therapies available for psoriasis: A systematic review of pharmacovigilance studies
- PMID: 39307356
- DOI: 10.1016/j.jaad.2024.09.022
Gastrointestinal adverse events associated with use of biologic therapies available for psoriasis: A systematic review of pharmacovigilance studies
Keywords: adverse event; biologic; gastrointestinal; pharmacovigilance; psoriasis; systematic review.
Conflict of interest statement
Conflicts of interest Dr Mufti has been a speaker for AbbVie and Janssen. Dr Yeung has been an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, Anacor, Arcutis, Astellas, Bausche, Baxalta, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Centocor, Coherus, Dermira, Forward, Fresenius Kabi, Galderma, Incyte, Janssen, LEO Pharma, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, and Xenon. Mr Sood, Ms Tarafdar, Mr Perlmutter, and Drs Maliyar and Sachdeva have no conflicts of interest to declare.
LinkOut - more resources
Full Text Sources